Je was op zoek naar: alzheimerjeve (Sloveens - Engels)

simptomatsko zdravljenje blage do zmerne alzheimerjeve demence.
symptomatic treatment of mild to moderately severe alzheimer’s dementia.

simptomatsko zdravljenje blage do zmerno hude alzheimerjeve demence.
symptomatic treatment of mild to moderately severe alzheimer’s dementia.

simptomatsko zdravljenje blage do zmerno težke alzheimerjeve demence.
symptomatic treatment of mild to moderately severe alzheimer’s dementia.

s staranjem prebivalstva se bo povečal tudi vpliv alzheimerjeve bolezni.
as europe's population becomes older, the impact of alzheimer's will become deeper too.

boljše razumevanje alzheimerjeve bolezni in drugih demenc s skupnimi evropskimi prizadevanji
better understanding of alzheimer’s disease and dementia through a shared european effort

zdravilo axura je bilo pri nadzorovanju simptomov alzheimerjeve bolezni učinkovitejše od placeba.
axura was more effective than placebo at controlling the symptoms of alzheimer’s disease.

zdravila exelon ni smiselno uporabljati pri pediatrični populaciji za zdravljenje alzheimerjeve bolezni.
there is no relevant use of exelon in the paediatric population in the treatment of alzheimer’s disease.

potrebno je boljše razumevanje demenc, zlasti alzheimerjeve bolezni in drugih nevrodegenerativnih oblik.
there is a clear need for improved understanding of dementias, in particular of alzheimer's disease and other neurodegenerative types.

med bolniki z diagnozo alzheimerjeve bolezni jih je 70 % starih 75 let in več.
70% of diagnosed ad patients are aged 75 and over.

zdravljenje naj prične in nadzoruje zdravnik, ki ima izkušnje z diagnozo in zdravljenjem alzheimerjeve demence.
treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of alzheimer's dementia.

na področju zdravja so med temi denimo raziskave raka, sladkorne bolezni, alzheimerjeve in parkinsonove bolezni.
in the field of health, this includes for example research on cancer, diabetes, alzheimer’s disease, and parkinson’s disease.

pediatrična populacija: zdravilo exelon ni primerno za uporabo pri pediatrični populaciji za zdravljenje alzheimerjeve bolezni.
paediatric population: there is no relevant use of exelon in the paediatric population in the treatment of alzheimer’s disease.

države eu so se odločile, da bodo prvo skupno načrtovanje raziskovalnih dejavnosti izvedle na področju alzheimerjeve bolezni in sorodnih obolenj.
alzheimer’s disease and related disorders have been identified by the eu countries as an area where the first joint programming of research activities should be launched.

(a) začetek pilotne pobude skupnega načrtovanja programov za zdravljenje nevrodegenerativnih bolezni, zlasti alzheimerjeve bolezni
(a) launch of the pilot joint programming initiative on combating neurodegenerative diseases, in particular alzheimer's

zdravljenje mora uvesti in nadzorovati zdravnik, ki je izkušen v diagnostiki in zdravljenju alzheimerjeve demence ali demence, povezane s parkinsonovo boleznijo.
treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of alzheimer’s dementia or dementia associated with parkinson’s disease.

podpora k ciljem usmerjenih raziskav o ključnih problemih na evropski ravni; določitev alzheimerjeve bolezni kot pilotne teme skupnega načrtovanja;
supporting targeted research on key problems at european level; develop alzheimer’s as a pilot of joint programming;

predlog poziva države članice, naj sprejmejo skupni pristop na evropski ravni prek skupnega načrtovanja programov na področju raziskav nevrodegenerativnih bolezni, zlasti alzheimerjeve bolezni.
the proposal invites the ms to adopt a common approach at european level through jp in research on nd, in particular ad.

oblikujejo strateški raziskovalni program, v katerih določijo srednje- do dolgoročne raziskovalne potrebe in cilje na področju nevrodegenerativnih bolezni, zlasti alzheimerjeve bolezni.
develop a strategic research agenda establishing medium to long term research needs and objectives in the area of neurodegenerative diseases, in particular alzheimer's.

delo za razvoj skupne pobude na področju nevrodegenerativnih bolezni, zlasti alzheimerjeve („alzheimerjeva pobuda“), poteka pod vodstvom držav članic;
work to develop a common initiative in the field of neuro-degenerative diseases, in particular alzheimer' ("alzheimer initiative") has been ongoing, led by the member states.

lestvica za ocenjevanje alzheimerjeve bolezni (adas- cog) (p=0, 003) in cibic- plus (p=0, 004) po 24 tednih (locf).
alzheimer´s disease assessment scale (adas-cog) (p=0.003) and cibic-plus (p=0.004) at week 24 (last observation carried forward (locf)).